It's still time to buy the dip on this stock Prosper Junior Bakiny (AstraZeneca): Last year, U.K.-based pharmaceutical giant ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

AstraZeneca has launched a Phase I clinical study titled An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Followi ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

This was the ADR's second consecutive day of losses.

The findings come from the global, multicenter, open-label, and single-arm Phase I/II SYRUS clinical trial (NCT06137118), ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

(Reuters) -AstraZeneca said on Tuesday that U.S. regulators have approved its precision drug Datroway to treat a type of lung ...

In all, their investment portfolio pulled in an estimated 54% return in 2024, more than double the S&P 500’s 25% gain — and ...

The UK's FTSE 100 saw its five-week winning streak halted, influenced by global tensions between Israel and Iran, and ...